Umecrine Mood AB
Umecrine Cognition AB is a company focused on developing novel drugs for neurological disorders with significant unmet medical needs. Their lead product, golexanolone, is a small molecule in development for treating neurological conditions such as hepatic encephalopathy and primary biliary cholangitis, aiming to improve cognition, alertness, and reduce fatigue. The company emphasizes high-efficiency clinical development and potential for indication expansion, collaborating with pharmaceutical partners and experts in medicine. Additionally, the company actively engages in clinical trials, updates via press releases, and shareholder meetings, demonstrating a strong commitment to advancing neurological therapeutics.
Industries
Nr. of Employees
small (1-50)
Umecrine Mood AB
Karolinska Institutet Science Park, Nanna Svartz väg 6A, 171 65 Solna, Sweden
Patents
Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
US-11123351-B2
View Details3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders
US-10351589-B2
View Details
Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
US-11123351-B2
View Details3.alpha.-ethynyl, 3.beta.-hydroxy-5.alpha.-pregnan-20-oxime for use in the treatment of CNS disorders
US-10351589-B2
View DetailsProducts
Oral small-molecule GABAA receptor–modulating CNS drug candidate
An orally administered small-molecule candidate designed to antagonize neurosteroid-mediated allosteric activation of GABAA receptors, developed for treatment of cognitive, motor and fatigue symptoms in select CNS-related disorders.
Oral small-molecule GABAA receptor–modulating CNS drug candidate
An orally administered small-molecule candidate designed to antagonize neurosteroid-mediated allosteric activation of GABAA receptors, developed for treatment of cognitive, motor and fatigue symptoms in select CNS-related disorders.
Services
Operational delivery and coordination of multi-site clinical studies including study design implementation, regulatory site approvals, patient recruitment and data collection across international sites.
Nonclinical efficacy and mechanistic pharmacology studies using disease-relevant animal models to evaluate candidate effects on neurological endpoints and support clinical translation.
Development, clinical validation and implementation of symptom severity scales and other trial-relevant outcome measures for use in clinical studies.
Operational delivery and coordination of multi-site clinical studies including study design implementation, regulatory site approvals, patient recruitment and data collection across international sites.
Nonclinical efficacy and mechanistic pharmacology studies using disease-relevant animal models to evaluate candidate effects on neurological endpoints and support clinical translation.
Development, clinical validation and implementation of symptom severity scales and other trial-relevant outcome measures for use in clinical studies.
Expertise Areas
- Clinical trial management
- Clinical pharmacology and PK studies
- Clinical outcome assessment development
- CNS small-molecule drug discovery
Key Technologies
- Oral small-molecule therapeutics
- GABAA receptor modulation
- CNS exposure and penetration assessment
- Preclinical disease models
News & Updates
Umecrine Cognition announced the resumption of patient inclusion in its Phase 1/2a clinical study of golexanolone for primary biliary cholangitis, indicating progress in their clinical development.
Umecrine Cognition announced that it will present validation and implementation data for a newly developed symptom severity scale for Primary Biliary Cholangitis at the EASL 2025 conference.
Umecrine Cognition announced the resumption of patient inclusion in its Phase 1/2a clinical study of golexanolone for primary biliary cholangitis, indicating progress in their clinical development.
Umecrine Cognition announced that it will present validation and implementation data for a newly developed symptom severity scale for Primary Biliary Cholangitis at the EASL 2025 conference.